Business Description
StageZero Life Sciences Ltd
NAICS : 325413
SIC : 3912
ISIN : CA36870T2065
Description
Financial Strength
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Equity-to-Asset | -26.91 | |||||
Debt-to-Equity | -0.17 | |||||
Debt-to-EBITDA | -1.34 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -517.81 | |||||
Beneish M-Score | -42.04 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 118.3 | |||||
3-Year EBITDA Growth Rate | -14.5 | |||||
3-Year EPS without NRI Growth Rate | 29.4 | |||||
3-Year FCF Growth Rate | 35.6 | |||||
3-Year Book Growth Rate | 17.7 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
14-Day RSI | 43.67 | |||||
6-1 Month Momentum % | -16.67 | |||||
12-1 Month Momentum % | -47.76 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.02 | |||||
Quick Ratio | 0.02 | |||||
Days Inventory | 13.24 | |||||
Days Sales Outstanding | 14.53 | |||||
Days Payable | 883.19 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -45.9 | |||||
Shareholder Yield % | -2.92 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 28.82 | |||||
Operating Margin % | -91.98 | |||||
Net Margin % | -78.3 | |||||
FCF Margin % | -1.83 | |||||
ROA % | -272.88 | |||||
ROIC % | -132.21 | |||||
3-Year ROIIC % | 342.41 | |||||
ROC (Joel Greenblatt) % | -509.16 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 1.74 | |||||
EV-to-EBIT | -3.78 | |||||
EV-to-EBITDA | -4.11 | |||||
EV-to-Revenue | 2.65 | |||||
EV-to-FCF | -141.31 | |||||
Earnings Yield (Greenblatt) % | -26.46 | |||||
FCF Yield % | -1.05 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
StageZero Life Sciences Ltd Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 1.91 | ||
EPS (TTM) (€) | -0.015 | ||
Beta | 1.49 | ||
Volatility % | 70.16 | ||
14-Day RSI | 43.67 | ||
14-Day ATR (€) | 0.000007 | ||
20-Day SMA (€) | 0.0175 | ||
12-1 Month Momentum % | -47.76 | ||
52-Week Range (€) | 0.0145 - 0.0335 | ||
Shares Outstanding (Mil) | 123.55 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
StageZero Life Sciences Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
StageZero Life Sciences Ltd Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
StageZero Life Sciences Ltd Frequently Asked Questions
What is StageZero Life Sciences Ltd(FRA:61N1)'s stock price today?
When is next earnings date of StageZero Life Sciences Ltd(FRA:61N1)?
Does StageZero Life Sciences Ltd(FRA:61N1) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |